HHMI awards $2 million to European Molecular Biology Organization

March 20, 2002

The Howard Hughes Medical Institute (HHMI) has awarded $2 million to the European Molecular Biology Organization (EMBO) to help launch the careers of young scientists in the Czech Republic, Hungary and Poland.

The four-year grant will support six scientists a year early in their careers. It links HHMI's International Research Scholars in the three countries with EMBO's Young Investigator Programme, (http://www.embo.org/projects/yip/). The HHMI/EMBO Scientists will receive 30,000 Euros (approximately $26,450) a year for four years and will be mentored by their more established HHMI-supported colleagues. Applications for the first year are due April 1.

The EMBO Young Investigator Programme, created in 2000, identifies promising molecular biologists in their first three years of heading independent laboratories. Currently, there are 78 EMBO Young Investigators in 17 out of 24 member countries.

HHMI launched its International Program in 1991 to recognize the international scope of modern biomedical research and the contributions of scientists outside the United States. The program supports international research scholars' work, scientific meetings of scholars and educational activities.

The Howard Hughes Medical Institute is a medical research organization whose principal mission is the conduct of biomedical research. It employs 324 investigators who conduct basic medical research in HHMI laboratories at 69 of the nation's leading research centers and universities. Through its complementary grants program, HHMI supports science education in the United States and a select group of researchers abroad.

Howard Hughes Medical Institute

Related Biomedical Research Articles from Brightsurf:

General data protection regulation hinders global biomedical research
The European Union (EU) General Data Protection Regulation (GDPR) was designed to give EU citizens greater protection and control of their personal data, particularly when transferred to entities outside the EU.

Novel educational program puts a human face on biomedical research
The goal of translational research is to speed research breakthroughs into clinical practice.

Biomedical research may miss key information by ignoring genetic ancestry
A new study of Black residents of four distinct US cities reveals variations in genetic ancestry and social status that underscore the inadequacy of using skin color as a proxy for race in research.

Advances in cryo-EM materials may aid cancer and biomedical research
Cryogenic-Electron Microscopy (cryo-EM) has been a game changer in the field of medical research, but the substrate, used to freeze and view samples under a microscope, has not advanced much in decades.

World-first program uncovers errors in biomedical research results
Just like the wrong ingredients can spoil a cake, so too can the wrong ingredients spoil the results in biomedical research.

Scientists poised to study reproducibility of Brazilian biomedical research
A project to assess the reproducibility of biomedical research in Brazil has been described today in the open-access journal eLife.

Transparency and reproducibility of biomedical research is improving
New research publishing Nov. 20 in the open-access journal PLOS Biology from Joshua Wallach, Kevin Boyack, and John Ioannidis suggests that progress has been made in key areas of research transparency and reproducibility.

As private funding of biomedical research soars, new risks arise
Academic medical centers (AMCs) in the US are navigating an increasing shift in research funding from historic public funding (e.g., NIH) to private sources such as pharma and biotech companies, foundations, and charities, raising a host of new issues related to collaborative research models, intellectual property rights, and scientific and ethical oversight.

BGRF scientists co-publish research paper on blockchain & AI for biomedical applications
Biogerontology Research Foundation Chief Science Officer (CSO) co-authored the landmark paper in the journal Oncotarget on the convergence of blockchain and AI to decentralize and galvanize healthcare and biomedical research.

Promising new drug for Hep B tested at Texas Biomedical Research Institute
Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

Read More: Biomedical Research News and Biomedical Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.